Pharmaceuticals

VivaCel Bio Initiates Phase 3 Clinical Trial of VBI-S for the Treatment of Hypovolemic Septic Shock

bexib
By bexib 0 Min Read

The trial will enroll 40 patients across the United States who have not responded adequately to standard hypovolemic septic shock treatments and are taking vasopressor drugs.

You Might Also Like

Researchers identify genetic change underlying rare pediatric immune disorder

UK dementia organisations launch new manifesto ahead of general election

Alzheimer’s treatment works, but stock prices fall

Parkinson’s Foundation Announces Grants for Community Programs Across 40 States

FDA Accepts Supplemental New Drug Application from Otsuka and Lundbeck for Brexpiprazole Treatment for Adults with Post-Traumatic Stress Disorder

Share This Article
Previous Article What happened to the mixed economy?
Next Article Congress Passes Bipartisan National Flag Act
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Eastman Credit Union enhances digital engagement with WaveCX
Banking
Allstate Corporation announced the possibility of use of the 2024 quarter results.
Insurance
FIS gives priority to the development of Agent AI
Banking
California Spring Loss: Internet or Gross?
Insurance